Erlotinib: all 574 studies that test it

Page 6 of 6. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00274833Phase 2
• Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLCStatus unknownNCT00268684Phase 3
• Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract CancerCompletedNCT00266097Phase 1
• Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)CompletedNCT00265824Phase 3
• Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00263822Phase 3
• Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryCompletedNCT00254384Phase 1
• Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic CancerCompletedNCT00243854Phase 1
• Erlotinib in Treating Patients With Progressive Glioblastoma MultiformeTerminatedNCT00227032Phase 1
• Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00217529Phase 1/2
• Study of Cetuximab in Combination With Tarceva in Patients With Solid TumorsCompletedNCT00207077Phase 1
• OSI-774 (Erlotinib, Tarceva) in Elderly PatientsCompletedNCT00200395Phase 2
• Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteCompletedNCT00193622Phase 2
• OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00193154Phase 2
• Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone TherapyCompletedNCT00148772Phase 2
• Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid CarcinomaCompletedNCT00144976Not applicable
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic FunctionCompletedNCT00139620Phase 1
• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated MesotheliomaCompletedNCT00137826Phase 2
• Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer PatientsCompletedNCT00137800Phase 2
• Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00126620Phase 1
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
• Tarceva and Capecitabine for Pancreatic CancerCompletedNCT00125021Phase 2
• Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal CancerCompletedNCT00123851Phase 2
• Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal CancerCompletedNCT00118261Phase 1
• Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2
• Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00113347Phase 1
• A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyCompletedNCT00109265Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00095225Phase 2
• A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00091663Phase 3
• Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00088959Phase 1
• Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder CancerCompletedNCT00088946Phase 2
• S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerCompletedNCT00087412Phase 2
• Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionTerminatedNCT00087269Phase 2
• Docetaxel and Erlotinib in Treating Older Patients With Prostate CancerCompletedNCT00087035Phase 2
• Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00086879Phase 2
• Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT00085553Phase 1
• Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00085280Not applicable
• A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell CarcinomaCompletedNCT00081614Phase 2
• Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00079053Phase 1
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
• Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00072631Phase 2
• Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00072072Phase 1
• Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerCompletedNCT00063947Phase 1
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerCompletedNCT00060411Phase 1
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerCompletedNCT00060307Phase 2
• Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a TaxaneCompletedNCT00059852Phase 2
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerCompletedNCT00055770Phase 1/2
• Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma MultiformeStatus unknownNCT00054496Phase 2
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerCompletedNCT00049101Phase 1/2
• A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung CancerCompletedNCT00047736Phase 3
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionCompletedNCT00047346Phase 1
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedTerminatedNCT00047333Phase 2
• Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach CancerCompletedNCT00045526Phase 2
• Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT00045201Phase 1
• Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung CancerCompletedNCT00043823Phase 1/2
• Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00042809Phase 1
• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.CompletedNCT00040183Phase 3
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCompletedNCT00039494Phase 2
• Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2
• OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00036647Phase 3
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid TumorsCompletedNCT00033241Phase 1
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction CancerCompletedNCT00032123Phase 2
• Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal CancerCompletedNCT00032110Phase 2
• Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the CervixCompletedNCT00031993Phase 2
• Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00030576Phase 1/2
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00030537Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerCompletedNCT00030485Phase 2
• Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00030446Phase 2
• Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic CancerCompletedNCT00026338Phase 3

← Erlotinib overview